1-溴-2-丁基苯 | 13397-98-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-2-丁基苯
• 英文名称: 1-bromo-2-butylbenzene
• 英文别名: 2-brom-n-butylbenzene；o-bromobutylbenzene；1-bromo-2-butyl-benzene；1-Brom-2-butyl-benzol；2-Brom-1-butyl-benzol；o-Brom-n-butylbenzol
• CAS: 13397-98-3
• 化学式: C₁₀H₁₃Br
• 分子量: 213.117
• InChiKey: UEVKWTASYVIROP-UHFFFAOYSA-N

物化性质

• 熔点：
  -44.89 °C
• 沸点：
  114 °C(Press: 18 Torr)
• 密度：
  1.2542 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2903999090

反应信息

• 作为反应物：
  描述：

  1-溴-2-丁基苯 生成 2-Butyl-benzhydrylchlorid
  参考文献：
  名称：

  烷基取代在药物中的作用-I。取代的二甲基氨基乙基苯甲醚。

  摘要：

  DOI：

  10.1021/jm50008a005
• 作为产物：
  描述：

  4-(2-溴苯基)-1-丁烯 在 一水合肼 、 邻硝基苯磺酰氯 作用下， 以 乙腈 为溶剂， 反应 18.0h， 生成 1-溴-2-丁基苯
  参考文献：
  名称：

  Iridium-Catalyzed Borylation of Secondary Benzylic C–H Bonds Directed by a Hydrosilane

  摘要：

  Most functionalizations of C-H bonds by main-group reagents occur at aryl or methyl groups. We describe a highly regioselective borylation of secondary benzylic C-H bonds catalyzed by an iridium precursor and 3,4,7,8-tetramethyl-1,10-phenanthroline as the ligand. The reaction is directed to the benzylic position by a hydrosilyl substituent. This hydrosilyl directing group is readily deprotected or transformed to other functional groups after the borylation reaction, providing access to a diverse set of secondary benzylboronate esters by C-H borylation chemistry.

  DOI：

  10.1021/ja403462b

文献信息

• Two-photon absorbing compounds and methods of making same
  申请人：The United States of America, as represented by the Secretary of the Air Force

  公开号：US10113065B1

  公开（公告）日：2018-10-30

  A two-photon absorbing (TPA) compound is provided, along with a method of making same. The TPA compound has a general structural formula: where A is an acceptor moiety that is connected to m number of diarylaminofluorene arms (m=1-3); in each diarylaminofluorene arms, R is selected from linear or branched alkyl chains having a general formula CnH2n+1, where n is in a range from 2 to 25; where R1, R2, and R3 are independently selected from H or C1-C4 alkyls; where R4 is selected from C1-C5 alkyls; and wherein R5 through R10 are independently selected from H, alkoxyls, alkyls, or aryls. A may be benzothiazol-2-yl, benzo[1,2-d:4,5-d′]bisthiazole-2,6-diyl, thiazolo[5,4-d]thiazole-2,5-diyl-, 1,3,5-triazine-2,4,6-triyl, 1,3,5-triazine-2,4,6-triyl, benzo[1,2-d:3,4-d′:5,6-d″]tristhiazole-2,5,8-triyl-, or dithieno[3,2-b:2′,3′-d]thiophene-2,6-diyl-.

  提供了一种双光子吸收（TPA）化合物，以及制造该化合物的方法。TPA化合物具有一般的结构公式：其中A是一个受体基团，它与m个二芳基氨基荧烷臂（m = 1-3）相连；在每个二芳基氨基荧烷臂中，R选自具有一般公式CnH2n+1的直链或支链烷基链，其中n的范围从2到25；其中R1、R2和R3独立地选自H或C1-C4烷基；其中R4选自C1-C5烷基；R5至R10独立地选自H、烷氧基、烷基或芳基。A可以是苯并噻唑-2-基，苯并[1,2-d:4,5-d']二噻唑-2,6-二基，噻唑[5,4-d]噻唑-2,5-二基，1,3,5-三嗪-2,4,6-三基，1,3,5-三嗪-2,4,6-三基，苯并[1,2-d:3,4-d':5,6-d"]三噻唑-2,5,8-三基，或二噻吩[3,2-b:2',3'-d]噻吩-2,6-二基。
• N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
  申请人：——

  公开号：US20020095035A1

  公开（公告）日：2002-07-18

  The present invention provides a method of inhibiting matrix metallo-proteinases (MMPs) in a patient in need thereof comprising administering to the patient an effective matrix metalloproteinase inhibiting amount of the N-carboxymethyl substituted benzolactams of formula (1): 1 wherein A is —OH or —NRR′. Such inhibitors are useful in treating neoplasms, atherosclorosis, and chronic inflammatory diseases. The present invention also provides novel N-carboxymethyl substituted benzolactams of formula (1a): 2 wherein A is —NRR′.

  本发明提供了一种抑制需要患者体内基质金属蛋白酶（MMPs）的方法，包括向患者施用N-羧甲基取代苯并内酰胺的有效基质金属蛋白酶抑制剂量，其化学式为（1）： 1 其中A为—OH或—NRR′。这些抑制剂在治疗肿瘤、动脉粥样硬化和慢性炎症性疾病方面是有用的。 本发明还提供了新颖的化学式（1a）中A为—NRR′的N-羧甲基取代苯并内酰胺。
• Iron-Catalyzed Remote Arylation of Aliphatic C–H Bond via 1,5-Hydrogen Shift
  作者：Bingwei Zhou、Hiroki Sato、Laurean Ilies、Eiichi Nakamura

  DOI：10.1021/acscatal.7b03458

  日期：2018.1.5

  arylation of 2-iodoalkylarenes with diphenylzinc selectively at the γ C–H bond of the alkyl side chain. Several lines of evidence suggest that the iron catalyst reacts with the aryl iodide moiety of the substrate to generate an aryliron intermediate that behaves in a radical manner and cleaves the aliphatic C–H bond through 1,5-hydrogen transfer; the resulting alkyliron intermediate undergoes reductive elimination

  催化量的铁（III）盐和N-杂环卡宾配体催化2-碘烷基芳烃与二苯基锌在烷基侧链的γC–H键上选择性地芳基化。有几条证据表明，铁催化剂与底物的芳基碘化物反应生成芳基铁中间体，该中间体以自由基的方式起作用，并通过1，5-氢转移裂解脂肪族CH键。所得的烷基铁中间体经过还原消除，得到芳基化产物。
• Selective mono-alkylation and arylation of aromatic dihalides by palladium-catalyzed cross-coupling with the Grignard and organozinc reagents
  作者：Akio Minato、Kohei Tamao、Tamio Hayashi、Keizo Suzuki、Makoto Kumada

  DOI：10.1016/s0040-4039(00)71521-8

  日期：1980.1

  Dibromobenzene, dibromothiophenes, dichloro- and dibromopyridine are highly selectively mono-alkylated and arylated with Grignard or organozinc reagents in the presence of palladium complexes as catalysts.

  在钯络合物作为催化剂的存在下，用格氏试剂或有机锌试剂将二溴苯，二溴噻吩，二氯吡啶和二溴吡啶高度选择性地单烷基化和芳基化。
• [EN] SUBSTITUTED 2-PYRAZINONE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 2-PYRAZINONE SUBSTITUÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014108820A1

  公开（公告）日：2014-07-17

  The present invention provides novel substituted 2-pyrazinone derivatives of formula (1) as protein kinase inhibitors, in which R1; R2, R3, R4, R5, R6, R7 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了一种新型的取代2-吡嗪酮衍生物，其化学式为(1)，作为蛋白激酶抑制剂，其中R1；R2，R3，R4，R5，R6，R7和'p'在说明书中给出了含义，以及其药学上可接受的盐，可用于治疗和预防疾病或紊乱，特别是在抑制激酶酶具有优势的疾病或紊乱中的应用，更具体地是BTK酶。本发明还提供了合成和给药激酶抑制剂化合物的方法。本发明还提供了包含至少一种激酶抑制剂化合物的药物配方，以及与其配合使用的药学上可接受的载体、稀释剂或赋形剂。